Accessing our website tells us you are happy to receive all our cookies. However you can change your cookie settings at any time.

Privacy & Cookies

Get in touch

  • Alliance Pharma PLC


  • Avonbridge House

  • Bath Road

  • Chippenham

  • Wiltshire, UK

  • SN15 2BB

  • United Kingdom

  • Registered Office, Chippenham

  • Registered in England, Company Number 04241478

You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Alliance in numbers

A proven track record

20 Years of operation
16.1 £m Free cash flow (2018)
22% See through revenue growth (2018)
37% Revenue from International star brands (2018)
35 Acquisitions to date

INVESTMENT CASE

Investors achieve more with Alliance

With a proven track record Alliance is committed to delivering sustained growth and value for investors.

Highly capable and scalable operation developed over 20 years

• Experienced management team
• Engaged and committed people
• Well-invested infrastructure

Our leadership team

Profitable, cash generative and dividend paying

• c.25% EBITDA margin
• Good cash conversion
• Progressive dividend policy
• Leverage currently 2.33 times

Financial highlights

Growth strategies via a proven business model

• Organic growth through selective promotion
• Additional growth through acquisitions
• Balanced portfolio
• No R&D risk

Our business model

Organic growth primarily from international star brands

• Kelo-Cote™
• Nizoral™
• MacuShield™
• Vamousse™

Our brands

Additional growth through acquisitions

• Very experienced team behind M&A – more than 35 deals in 20 years
• Expertise in sourcing, executing and integrating acquisitions
• Strong cash generation supports deal flow

Partnerships

Extensive geographic reach

• Direct presence in Western Europe, the US and the Far East
• Extensive international partnering network reaching over 90 countries

Why partner with alliance

Diversified Portfolio spreads risk

Revenues derive from more than 90 pharmaceutical and consumer healthcare products spanning multiple therapy areas and geographies

Our product range